Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis 2003;16(4):389-95
Date
10/31/2003Pubmed ID
14584489DOI
10.1159/000072562Scopus ID
2-s2.0-0141676273 (requires institutional sign-in at Scopus site) 163 CitationsAbstract
Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.
Author List
Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, Welch MA, Zivin J, SPARCL InvestigatorsAuthor
Diane S. Book MD Associate Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Cholesterol
Double-Blind Method
Endpoint Determination
Female
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Multicenter Studies as Topic
Patient Selection
Prospective Studies
Pyrroles
Randomized Controlled Trials as Topic
Research Design
Secondary Prevention
Stroke
